Pharmaceutical Business review

Otsuka seeks Japanese approval for dopamine agonist transdermal patch

Rotigotine Patch has been developed as a treatment for Parkinson’s disease and restless legs syndrome.

The patch will provide a continuous release of the drug substance and maintains a clinically effective blood drug concentration for 24 hours to achieve stable effects.

Rotigotine Patch was developed to lessen the symptoms that can occur during the day or night and to provide patients with a convenient form of drug treatment, the company said.